Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III maintenance Tarceva versus delayed Tarceva at progression in advanced non-small cell lung cancer
2010-024468-16Phase 3Completed
- Sponsor
- Roche
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Maintenance Tarceva with Placebo then Tarceva at progression (2 arms). Primary endpoint: Overall survival. Started May 2011; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-024468-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024468-16.